Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 555

1.

Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.

Ghosn J, De Montgolfier I, Cornélie C, Dominguez S, Pérot C, Peytavin G, Marcelin AG, Pauchard M, Ouagari Z, Bonmarchand M, Agher R, Calvez V, Bricaire F, Dommergues M, Katlama C, Tubiana R.

Antimicrob Agents Chemother. 2008 Apr;52(4):1542-4. doi: 10.1128/AAC.01301-07. Epub 2008 Feb 4.

2.

A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).

Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M Jr, van der Ende ME.

Antivir Ther. 2003 Oct;8(5):455-61.

PMID:
14640393
3.

Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.

Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM; BestQol Study Group.

Antivir Ther. 2004 Dec;9(6):979-85.

PMID:
15651756
4.

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.

Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):478-82.

PMID:
12473835
5.

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL; South African Intrapartum Nevirapine Trial (SAINT) Investigators.

J Infect Dis. 2003 Mar 1;187(5):725-35. Epub 2003 Feb 24.

PMID:
12599045
6.
7.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
8.

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jiménez E, McSherry G, Mofenson L.

Antimicrob Agents Chemother. 2007 Jun;51(6):2208-10. Epub 2007 Apr 9.

9.

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.

PMID:
11981365
10.

Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy.

Grubert TA, Wintergerst U, Lutz-Friedrich R, Belohradsky BH, Rolinski B.

AIDS. 1999 Jul 30;13(11):1430-1. No abstract available.

PMID:
10449309
11.

Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.

Solas C, Petit N, Orticoni M, Durand A, Gastaut JA, Lacarelle B.

Pathol Biol (Paris). 2002 Nov;50(9):565-7.

PMID:
12490421
12.

Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.

Patel AK, Patel KK, Sharma R, Ranjan RR, Shukla RK, Patel JA.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):231-3. doi: 10.1097/QAI.0b013e318189ab4e. No abstract available.

PMID:
19155769
13.

Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).

Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F; ANRS 109 VISTA Study Group.

Antivir Ther. 2006;11(7):889-99.

PMID:
17302251
14.

Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites.

Read JS, Cahn P, Losso M, Pinto J, Joao E, Duarte G, Cardoso E, Freimanis-Hance L, Stoszek SK; NISDI Perinatal Study Group.

Obstet Gynecol. 2007 Jun;109(6):1358-67.

PMID:
17540808
15.

Antiretroviral drugs in the treatment of people living with human immunodeficiency virus: experience in a south Indian tertiary referral centre.

Kumarasamy N, Solomon S, Peters E, Amalraj RE, Purnima M, Ravikumar B, Yepthomi T, Thyagarajan SP.

J Assoc Physicians India. 2000 Apr;48(4):390-3.

PMID:
11273171
16.
17.

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, Grossi G, Motta R, Viale P.

Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306. Epub 2012 Jan 21.

PMID:
22263609
18.

Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?

Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, Teglas JP, Ekoukou D, Blanche S, Mandelbrot L.

Clin Infect Dis. 2012 May;54(9):1348-60. doi: 10.1093/cid/cis198. Epub 2012 Mar 28.

PMID:
22460969
19.

HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

Tamburrini E, Ravizza M, Floridia M, Tibaldi C, Alberico S, Anzidei G, Maccabruni A, Meloni A, Antoni AD, Mori F, Dalzero S, Conservan V, Pinnetti C, Ferrazzi E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

Antivir Ther. 2008;13(4):519-27.

PMID:
18672530
20.

Antiretroviral medications during pregnancy for therapy or prophylaxis.

Stek AM.

Curr HIV/AIDS Rep. 2009 May;6(2):68-76. Review.

PMID:
19358777

Supplemental Content

Support Center